CNS & Neurological Disorders - Drug Targets

Formerly Current Drug Targets - CNS & Neurological Disorders

Editor-in-Chief

Edoardo Spina
Department of Clinical and Experimental Medicine
University of Messina
Policlinico Universitario
Via Consolare Valeria
Messina
(Italy)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 6 Issue: 2, April

Editorial [Hot Topic:Depression (Part 1) (Guest Editors: John H. Kehne and Ronald S. Duman)]

Volume:6   Issue: 2
Pp: 85-86
Ronald S. Duman and John H. Kehne
DOI: 10.2174/187152707780363249
Published on: 01 March, 2012

Metabotropic Glutamate Receptors in the Control of Mood Disorders

Volume:6   Issue: 2
Pp: 87-100
Jeffrey M. Witkin, Gerard J. Marek, Bryan G. Johnson and Darryle D. Schoepp
DOI: 10.2174/187152707780363302
Published on: 01 March, 2012

The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder

Volume:6   Issue: 2
Pp: 101-115
Christopher Pittenger, Gerard Sanacora and John H. Krystal
DOI: 10.2174/187152707780363267
Published on: 01 March, 2012

AMPA Receptors in the Therapeutic Management of Depression

Volume:6   Issue: 2
Pp: 117-126
D. Bleakman, A. Alt and J. M. Witkin
DOI: 10.2174/187152707780363258
Published on: 01 March, 2012

GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action

Volume:6   Issue: 2
Pp: 127-140
Gerard Sanacora and Aybala Saricicek
DOI: 10.2174/187152707780363294
Published on: 01 March, 2012

Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)

Volume:6   Issue: 2
Pp: 141-149
Phil Skolnick and Anthony S. Basile
DOI: 10.2174/187152707780363285
Published on: 01 March, 2012

Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development

Volume:6   Issue: 2
Pp: 151-160
Keith Q. Tanis, Samuel S. Newton and Ronald S. Duman
DOI: 10.2174/187152707780363276
Published on: 01 March, 2012